PXL/HO/Cir-098/2023-24                                                                            Date: 14.02.2024

Hyderabad

Subject: URGENT Survey on India-Australia Trade Under ECTA & CoO Challenges

Greetings from Pharmexcil!

As the members are aware that the India-Australia Economic Cooperation and Trade Agreement (ECTA) came into force on December 29, 2022. Since then, our Department of Commerce, Trade Policy Division has been keeping a track of the quantum of exports going through the FTA route. The Department of Commerce receives monthly data on preferential exports to Australia, along with cumulative figures. Upon analyzing this data, it has come to our attention that pharmaceutical exports to Australia via the FTA route have not met expectations. It has further come to our attention that exporters are not taking advantage of the tariff concessions during their exports.

In this regard, we would like to understand from our members’ exporters about possible reasons for the lack of usage of the FTA route for their exports. We urge exporters to kindly review the attached information FAQs and the Tariff Commitments by Australia.

Pharmexcil is keen to gain insights into the challenges and difficulties encountered in obtaining the Certificate of Origin (CoO), with the aim of facilitating appropriate action by the Department of Commerce to address these issues.We request our members to kindly fill the Google form to enable the Council to understand and analyze the issues been faced.  

Link: https://docs.google.com/forms/d/e/1FAIpQLScu_G6mvJSvSjMvO-hO9eAvYkc1y9HWX9x72M5-3Ptp3_qLEg/viewform?usp=pp_url

We look forward to your prompt response at the earliest. .

With regards,

Uday Bhaskar

Director General

ENCL: FAQs on UAE & AUS India - ECTA'